Democratic presidential nominee Joe BidenJoe BidenMcConnell challenger dodges court packing question ‘Hamilton’ cast to reunite for Biden fundraiser Trump relishes return to large rallies following COVID-19 diagnosis MORE’s son-in-law, Howard Krein, has continued his work at an investment firm overseeing health care solutions to COVID-19 while also advising the Biden campaign on the pandemic, sparking potential conflict-of-interest concerns, according to Politico.
In March, StartUp Health, where Krein serves as chief medical officer, announced a new initiative to invest in entrepreneurs with various “solutions for mitigating, managing, or treating coronavirus or future pandemics.”
A month later, StartUp Health announced it would be investing $1 million across 10 different startups with potential public health solutions to the coronavirus.
This came around the same time that Bloomberg and The New York Times both reported Krein among those taking part in daily Biden campaign briefing calls on health policy.
The first presidential debate was less an argument over policies and ideas than a boxing match. But there was at least one brief exchange that bordered on an ideological debate.
“We prefer a vaccine,” said Democratic presidential nominee Joe BidenJoe BidenFederal judge shoots down Texas proclamation allowing one ballot drop-off location per county Sanders endorses more than 150 down-ballot Democrats Debate commission cancels Oct. 15 Trump-Biden debate MORE about the COVID-19 pandemic. “But I don’t trust [President TrumpDonald John TrumpFederal judge shoots down Texas proclamation allowing one ballot drop-off location per county Nine people who attended Trump rally in Minnesota contracted coronavirus Schiff: If Trump wanted more infections ‘would he be doing anything different?’ MORE] at all, and neither do you. I know you don’t. What we trust is a scientist.”
“You don’t trust Johnson & Johnson, Pfizer?” the president responded.
Unfortunately, the discussion then drifted
By Nupur Anand
MUMBAI (Reuters) – Indian bankers fear the government’s decision to waive some interest payments on loans under a COVID-19 support plan will create unnecessary work for lenders and lead to more litigation, without providing much of a boost for the sagging economy.
In an Oct. 2 filing with the Supreme Court, seen by Reuters, the government said it is amending a controversial clause in a relief plan that allowed distressed borrowers to skip repayments for six months but then charged them “interest-on-interest” on the delayed payments, putting them deeper in debt.
The change will waive the compounded interest component on small business loans and some personal debts from March to August.
The government will bear the cost, which could be as high as $1 billion, according to analysts.
But for Indian lenders saddled with over $120 billion of bad loans and a coronavirus-induced collapse in demand, the
(Bloomberg) — India’s top court asked the government and banks how they plan to waive deferred interest on loans for small borrowers and whether similar relief measures could be provided to other sectors.
The Supreme Court on Monday asked lawyers from the government and Reserve Bank of India to submit information on the measures they plan to take on waiving some of the interest and recasting loans for stressed borrowers. The court will listen to this feedback on Oct. 13.
Prime Minister Narendra